EGFR and non-small cell lung carcinoma: Two groups have reported that patients who suffered from non-small-cell lung cancer (NSCLC) experienced an improvement in diabetes after erlotinib (an EGFR inhibitor) treatment (Portero-Otin et al., 2002; Costa and Huberman 2006; Brooks 2012).